trial

A Long-Term Study in Schizophrenia

NCTId NCT01487083
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Terminated
Enrollment 282 (estimated)
Sponsored by Eli Lilly and Company
Primary completion 2012-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Terminated
Enrollment
282 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2011-12
Primary completion
2012-10
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Pomaglumetad

Sponsors

Eli Lilly and CompanyLead Sponsor

Investigators

1
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)Study Director

Sites

51 total
Cerritos, United StatesEscondido, United StatesGarden Grove, United StatesLong Beach, United StatesSan Diego, United StatesSherman Oaks, United StatesTorrance, United StatesWashington D.C., United StatesCoral Gables, United StatesLauderhill, United StatesMaitland, United StatesNorth Miami, United States

Linked catalysts

1
A Long-Term Study in Schizophrenia — primary completion2012-10

Facts & assertions

4 sourced
Enrollment
282
Phase
PHASE3
Primary Completion Date
2012-10
Status
TERMINATED
relationships
The graph out of here
drug
Pomaglumetad
drug
lead_sponsor
Eli Lilly and Company
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
person